|4.23||+0.0800||+1.93%||Vol 61.60K||1Y Perf 90.50%|
|Jun 15th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||9.50||Analyst Rating||Strong Buy 1.00|
|Potential %||124.59||Finscreener Ranking||★★★★★ 60.62|
|Insiders Trans % 3/6/12 mo.||100/100/100||Value Ranking||★★★+ 53.72|
|Insiders Value % 3/6/12 mo.||100/100/100||Growth Ranking||★★★+ 56.17|
|Insiders Shares Cnt. % 3/6/12 mo.||100/100/100||Income Ranking||— -|
|Market Cap||126.69M||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||39.59||Earnings Date||15th Jun 2021|
Today's Price Range
5 Year PE Ratio Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.11|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||113.30K|
|Avg. Monthly Volume||118.39K|
|Avg. Quarterly Volume||420.84K|
Anixa Biosciences Inc. (NASDAQ: ANIX) stock closed at 4.23 per share at the end of the most recent trading day (a 1.93% change compared to the prior day closing price) with a volume of 61.60K shares and market capitalization of 126.69M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 4 people. Anixa Biosciences Inc. CEO is Amit Kumar.
The one-year performance of Anixa Biosciences Inc. stock is 90.5%, while year-to-date (YTD) performance is 37.79%. ANIX stock has a five-year performance of %. Its 52-week range is between 1.7 and 8.09, which gives ANIX stock a 52-week price range ratio of 39.59%
Anixa Biosciences Inc. currently has a PE ratio of -10.40, a price-to-book (PB) ratio of 9.87, a price-to-sale (PS) ratio of 242.52, a price to cashflow ratio of 18.90, a PEG ratio of 2.32, a ROA of -90.26%, a ROC of -100.90% and a ROE of -98.53%. The company’s profit margin is -%, its EBITDA margin is -1 854.50%, and its revenue ttm is $512.50 Thousand , which makes it $0.02 revenue per share.
Of the last four earnings reports from Anixa Biosciences Inc., there were 2 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.11 for the next earnings report. Anixa Biosciences Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Anixa Biosciences Inc. is Strong Buy (1), with a target price of $9.5, which is +124.59% compared to the current price. The earnings rating for Anixa Biosciences Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Anixa Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Anixa Biosciences Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 20.65, ATR14 : 0.30, CCI20 : 48.73, Chaikin Money Flow : -0.02, MACD : -0.01, Money Flow Index : 63.07, ROC : 6.28, RSI : 51.98, STOCH (14,3) : 44.09, STOCH RSI : 0.43, UO : 44.99, Williams %R : -55.91), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Anixa Biosciences Inc. in the last 12-months were: Amit Kumar (Buy at a value of $120 680), Arnold Baskies (Buy at a value of $87 100), Emily Gottschalk (Buy at a value of $121 028), Lewis H. Titterton (Buy at a value of $515 380)
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.